Thyroid Hormone Therapy for Obesity and Nonthyroidal Illnesses: A Systematic Review
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
CONTEXT: Thyroid hormone therapy to enhance weight loss in obesity during caloric deprivation and to improve morbidity and mortality in adults with nonthyroidal illnesses remains controversial. OBJECTIVE: The aim of this study was to conduct a systematic review evaluating effectiveness and risks of T(3) and/or T(4) therapy in these populations. DATA SOURCES: Electronic databases and reference lists were searched. STUDY SELECTION: Studies with comparable control groups comparing T(3) and/or T(4) therapy to placebo in randomized controlled trials (RCTs) or prospective observational studies were selected. DATA EXTRACTION: Three reviewers performed serial abstraction. DATA SYNTHESIS: During caloric deprivation of obese subjects, T(3) therapy decreased serum TSH and T(4) concentrations. Consistent effects of T(3) or T(4) on weight loss, protein breakdown, metabolic rate, and heart rate could not be established. In euthyroid cardiac patients, T(3) decreased TSH and free T(4) levels, without consistent effects of T(3) or T(4) on heart rate, cardiac output, or systemic vascular resistance. Mortality increased 3.3-fold with T(4) therapy in acute renal failure patients, whereas an effect in cardiac, critically ill, and burn patients could not be established. Equivalence testing indicated that larger RCTs are required to determine whether thyroid hormone therapy alters end-points in obesity or nonthyroidal illnesses. LIMITATIONS: Numbers of usable unique studies were small, numbers of patients in each study were inadequate, end-points were variable, few RCTs were performed, and study quality of non-RCTs was poor. CONCLUSIONS: Available data are inconclusive regarding effectiveness of thyroid hormone therapy in treating obesity or nonthyroidal illnesses, whereas data support that such therapy induces subclinical hyperthyroidism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical Significance of Subclinical Thyroid Dysfunction
Biondi, B., & Cooper, D. S. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0043 · Cited by 1,418 · cited 3×
“increased atrial arrhythmias, and decreased systolic time intervals (11, 81) as well as increased average 24-h heart rate and decreased pulse wave arrival time.”
BackgroundPeeters, R. P., Wouters, P. J., Kaptein, E., van Toor, H., Visser, T. J., & Van den Berghe, G. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-022013 · Cited by 452 · cited 1×
“Controversy continues as to whether thyroid hormone therapy has beneficial or detrimental effects in euthyroid obese subjects undergoing caloric deprivation and in euthyroid adult patients during nonthyroidal illnesses (1, 3, 12).”
BackgroundSelf-citationBiondi, B. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.12.4701 · Cited by 356
Pingitore, A., Galli, E., Barison, A., Iervasi, A., Scarlattini, M., Nucci, D., L’Abbate, A., Mariotti, R., & Iervasi, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2210 · Cited by 279 · cited 1×
“Nonthyroidal illnesses: n=7 (47-53) Full-length articles abstracted onto evidence tables: n= 44 Full-length articles excluded for assessment for study design reasons: n= 23 Reasons for exclusion: • Data not extractable: n=6 (13-18)* • End-points not included in study: n=2 (19,20) • Case study: n=1 (21) • Before and du…”
Effect of Tri-Iodothyronine Replacement on the Metabolic and Pituitary Responses to Starvation
Gardner, D. F., Kaplan, M. M., Stanley, C. A., & Utiger, R. D. (1979) · New England Journal of Medicine · doi:10.1056/nejm197903153001102 · Cited by 239
Lean Body Mass Is a Major Determinant of Levothyroxine Dosage in the Treatment of Thyroid Diseases
Santini, F., Pinchera, A., Marsili, A., Ceccarini, G., Castagna, M. G., Valeriano, R., Giannetti, M., Taddei, D., Centoni, R., Scartabelli, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1306 · Cited by 226 · cited 1×
“Lean rather than total body mass may be a major determinant of T4 dose (83), which may also apply to T3 dose, accounting for TSH suppression with physiological doses of T3 expressed per 70 kg body weight in obese subjects.”
BackgroundDe Groot, L. J. (2006) · Critical Care Clinics · doi:10.1016/j.ccc.2005.10.001 · Cited by 188
The Impact of Overt and Subclinical Hyperthyroidism on Skeletal Muscle
Brennan, M. D., Powell, C., Kaufman, K. R., Sun, P. C., Bahn, R. S., & Nair, K. S. (2006) · Thyroid · doi:10.1089/thy.2006.16.375 · Cited by 155 · cited 3×
“Thyroid Hormone Therapy for Nonthyroidal States J Clin Endocrinol Metab, October 2009, 94(10):3663–3675”
BackgroundMedium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy
Moruzzi, P., Doria, E., & Agostoni, P. G. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00281-1 · Cited by 135 · cited 6×
“Koppeschaar, 1983 (39) IC Obese CD/e Both 30 10, 8 1 3 8 Obs Poor 5 (2, 2, 1) Koppeschaar, 1983 (40) IC Obese CD/e Both 30 10, 8 1 4 5 Obs Poor 4 (1, 2, 1) Osburne, 1983 (41) IC Obese CD/b Both 19–51 8, 9 1 1 2 10 Obs Poor 2 (1, 1, 0) Pasquali, 1984 (42) NS Obese CD/f Both 37 7, 7 1 4 16 RCT Good 8 (2, 3, 3) Wolman, 1…”
BackgroundInfluentialHaemodynamic changes following treatment of subclinical and overt hyperthyroidism
Faber, J., Wiinberg, N., Schifter, S., & Mehlsen, J. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450391 · Cited by 104 · cited 2×
“increased atrial arrhythmias, and decreased systolic time intervals (11, 81) as well as increased average 24-h heart rate and decreased pulse wave arrival time.”
Background
Cited by
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
“Efforts to use LT3 are based on studies showing decreased serum T3 with subsequent decreased basal metabolic rate in obese subjects placed on calorierestricted diets (447,558).”
InfluentialGarber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
“Because of the negative impact on nitrogen balance, cardiovascular factors, bone, and affective status, supraphysiological doses of thyroid hormone as used in the past (252,253) should not be employed as an adjunct to weight loss programs in patients with or without hypothyroidism (254).”
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053
Thyroid and Obesity: An Intriguing Relationship
Biondi, B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1245 · Cited by 330
MECHANISMS IN ENDOCRINOLOGY: Heart failure and thyroid dysfunction
Biondi, B. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0627 · Cited by 291
Beyond Low Plasma T3: Local Thyroid Hormone Metabolism during Inflammation and Infection
Boelen, A., Kwakkel, J., & Fliers, E. (2011) · Endocrine Reviews · doi:10.1210/er.2011-0007 · Cited by 287
Treatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259
Obesity: A critical risk factor in the COVID‐19 pandemic
Kwok, S., Adam, S., Ho, J. H., Iqbal, Z., Turkington, P., Razvi, S., Le Roux, C. W., Soran, H., & Syed, A. A. (2020) · Clinical Obesity · doi:10.1111/cob.12403 · Cited by 255
Santini, F., Marzullo, P., Rotondi, M., Ceccarini, G., Pagano, L., Ippolito, S., Chiovato, L., & Biondi, B. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0067 · Cited by 240
Christoffersen, B. Ø., Sanchez‐Delgado, G., John, L. M., Ryan, D. H., Raun, K., & Ravussin, E. (2022) · Obesity · doi:10.1002/oby.23374 · Cited by 142
“Thyroid extracts were once used for weight- loss induction (48), and although a low dose of thyroid hormones may aid weight maintenance and the preservation of lean mass, hyperthyroidism or thyrotoxicosis in euthyroid patients (49) along with adverse effects on bone metabolism and cardiac mass and/or function are sign…”
BackgroundForini, F., Kusmic, C., Nicolini, G., Mariani, L., Zucchi, R., Matteucci, M., Iervasi, G., & Pitto, L. (2014) · Endocrinology · doi:10.1210/en.2014-1106 · Cited by 132
Hoefig, C. S., Köhrle, J., Brabant, G., Dixit, K., Yap, B., Strasburger, C. J., & Wu, Z. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2680 · Cited by 78
Johannsen, D. L., Galgani, J. E., Johannsen, N. M., Zhang, Z., Covington, J. D., & Ravussin, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040837 · Cited by 57
Thyroid hormone T3 counteracts STZ induced diabetes in mouse
Verga Falzacappa, C., Mangialardo, C., Madaro, L., Ranieri, D., Lupoi, L., Stigliano, A., Torrisi, M. R., Bouchè, M., Toscano, V., & Misiti, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019839 · Cited by 52
“As reported by Kaptein et al [34], thyroid hormone treatment in obese patients with nonthyroidal illnesses provoked only a subclinical risk and no significant side effects concerning either weight loss or heart rate; neither mortality was worsened by THs treatment.”
Mammen, J. S., McGready, J., Ladenson, P. W., & Simonsick, E. M. (2017) · Thyroid® · doi:10.1089/thy.2017.0211 · Cited by 34
“Additionally, changes in thyroid homeostasis might reflect appropriate adaptation to other morbidities, such as occurs with non-thyroidal illness—metabolic changes for which pharmacologic intervention has not been shown to be beneficial (8).”
Polotsky, H. N., Brokhin, M., Omry, G., Polotsky, A. J., & Tuttle, R. M. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04264.x · Cited by 32
Targeting skeletal muscle mitochondrial health in obesity
Pileggi, C. A., Hooks, B. G., McPherson, R., Dent, R. R. M., & Harper, M.-E. (2022) · Clinical Science · doi:10.1042/cs20210506 · Cited by 21
Review on obesity management: diet, exercise and pharmacotherapy
Peri, K., & Eisenberg, M. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000246 · Cited by 13
Metadata
- Authors
- Kaptein, E. M., Beale, E., & Chan, L. S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-10-01
- Volume
- 94
- Issue
- 10
- Pages
- 3663-3675
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2111458555
- Cited by
- 111
- References
- 10
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.